LESLIE ETHRIDGE: Open Payments
NPI 1639804560 · DOTHAN, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,034 in 133 payments from 18 companies in 2025. Trend: 2023 $1,380 · 2024 $2,553 · 2025 $3,034
Food & beverage: $3,000Education: $34
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 13 | $624 |
| GlaxoSmithKline, LLC. | 27 | $543 |
| Takeda Pharmaceuticals U.S.A., Inc. | 14 | $296 |
| GENZYME CORPORATION | 11 | $243 |
| Amgen Inc. | 13 | $229 |
| Regeneron Healthcare Solutions, Inc. | 11 | $215 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 10 | $214 |
| United Therapeutics Corporation | 8 | $155 |
| Verona Pharma, Inc. | 6 | $114 |
| Viatris Specialty LLC | 5 | $102 |
Products named: TEZSPIRE, DUPIXENT, TRELEGY ELLIPTA, NUCALA, FASENRA, Tyvaso, GLASSIA, Ohtuvayre.
Industry payments across AL — which companies pay providers there.
